The SERM / SERD Bazedoxifene Disrupts ESR 1 Helix 12 to Overcome Acquired Hormone 1 Resistance in Breast Cancer Cells 2

[1]  M. Warmuth,et al.  Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA) , 2018, Cancer Chemotherapy and Pharmacology.

[2]  May M. Y. Liang-Chu,et al.  Abstract NG05: Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics , 2018, Endocrinology.

[3]  F. Lombardo,et al.  Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. , 2018, Journal of medicinal chemistry.

[4]  A. Bardia,et al.  Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC) , 2018 .

[5]  J. Flanagan,et al.  Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer , 2018 .

[6]  S. Chandarlapaty,et al.  Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. , 2017, Cancer discovery.

[7]  S. Chandarlapaty,et al.  Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.

[8]  A. Rabow,et al.  AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models. , 2016, Cancer research.

[9]  A. Rabow,et al.  Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist. , 2015, Journal of medicinal chemistry.

[10]  E. Nelson,et al.  Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. , 2015, Endocrine-related cancer.

[11]  R. Schiff,et al.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.

[12]  Andiliy G. Lai,et al.  Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. , 2015, Journal of medicinal chemistry.

[13]  M. Ellis,et al.  Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer , 2015, Clinical Cancer Research.

[14]  J. Katzenellenbogen,et al.  Estrogen receptor alpha/co-activator interaction assay: TR-FRET. , 2015, Methods in molecular biology.

[15]  James X. Sun,et al.  Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer , 2014, Clinical Cancer Research.

[16]  Klaus Schulten,et al.  Rapid parameterization of small molecules using the force field toolkit , 2013, J. Comput. Chem..

[17]  David Chen,et al.  ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.

[18]  E. Nelson,et al.  Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease , 2013, Clinical Cancer Research.

[19]  M. J. Chalmers,et al.  HDX Workbench: Software for the Analysis of H/D Exchange MS Data , 2012, Journal of The American Society for Mass Spectrometry.

[20]  J. Katzenellenbogen,et al.  Exploration of Dimensions of Estrogen Potency , 2011, The Journal of Biological Chemistry.

[21]  E. Knudsen,et al.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.

[22]  R. Houtman,et al.  Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor γ Cofactor* , 2009, Molecular & Cellular Proteomics.

[23]  E. Messalli,et al.  Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update , 2009, International journal of women's health.

[24]  B. Katzenellenbogen,et al.  NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses. , 2008, Nature chemical biology.

[25]  D. Biskobing.  Update on bazedoxifene: A novel selective estrogen receptor modulator , 2007, Clinical interventions in aging.

[26]  B. Komm,et al.  Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. , 2005, Endocrinology.

[27]  J. Katzenellenbogen,et al.  Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. , 2005, Molecular endocrinology.

[28]  J. Katzenellenbogen,et al.  A Proteomic Microarray Approach for Exploring Ligand-initiated Nuclear Hormone Receptor Pharmacology, Receptor Selectivity, and Heterodimer Functionality* , 2005, Molecular & Cellular Proteomics.

[29]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[31]  J. Katzenellenbogen,et al.  Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. , 2002, Molecular endocrinology.

[32]  B. O’Malley,et al.  Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1 , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[35]  Zhongqi Zhang,et al.  Determination of amide hydrogen exchange by mass spectrometry: A new tool for protein structure elucidation , 1993, Protein science : a publication of the Protein Society.

[36]  W. McGuire,et al.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. , 1978, Endocrinology.

[37]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[38]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[39]  Meenakshi Gupta,et al.  Duavee: a tissue-selective estrogen complex for menopausal symptoms and prevention of osteoporosis , 2015 .

[40]  G. Hospers,et al.  Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. , 2015, Cancer discovery.